KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2025)

GoodRx Holdings' Cost of Revenue history spans 7 years, with the latest figure at -$123.8 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 231.97% year-over-year to -$123.8 million; the TTM value through Dec 2025 reached $57.6 million, down 80.07%, while the annual FY2025 figure was $57.6 million, 84.31% down from the prior year.
  • Cost of Revenue for Q4 2025 was -$123.8 million at GoodRx Holdings, down from $83.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $242.2 million in Q3 2021 and bottomed at -$139.6 million in Q3 2022.
  • The 5-year median for Cost of Revenue is $47.4 million (2022), against an average of $49.1 million.
  • The largest annual shift saw Cost of Revenue soared 791.35% in 2022 before it crashed 231.97% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $106.5 million in 2021, then tumbled by 83.7% to $17.4 million in 2022, then decreased by 12.62% to $15.2 million in 2023, then skyrocketed by 518.52% to $93.8 million in 2024, then plummeted by 231.97% to -$123.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Cost of Revenue are -$123.8 million (Q4 2025), $83.5 million (Q3 2025), and $13.4 million (Q2 2025).